CD274 and non-small cell lung carcinoma: Subsequently, PD-1 inhibitors (nivolumab, pembrolizumab, cemiplimab) and PD-L1 inhibitors (atezolizumab, avelumab, durvalumab) were approved, and the spectrum of indications was widely extended to include melanoma, non-small-cell lung cancer (NSCLC), renal cell carcinoma, Hodgkin’s lymphoma, head and neck squamous cell cancer, and hepatocellular carcinoma [2].